Posted by Michael Wonder on 21 Jul 2025
Bristol Myers Squibb’s supplemental new drug application for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis accepted for review across four regions globally
21 July 2025 - Bristol Myers Squibb today announced that the US FDA has accepted for review the supplemental new drug application for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
The FDA has assigned a PDUFA goal date of 6 March 2026.
